Evidence map›Paper›PMID 19589835›Full record

ArticleMicrobiology (Reading, England)2009

Deletion of Braun lipoprotein gene (lpp) and curing of plasmid pPCP1 dramatically alter the virulence of Yersinia pestis CO92 in a mouse model of pneumonic plague.

Stacy L Agar, Jian Sha, Wallace B Baze, Tatiana E Erova, Sheri M Foltz, Giovanni Suarez, Shaofei Wang, Ashok K Chopra

Abstract read
In one paragraph

Article in Microbiology (Reading, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Biomolecules · 2020
    Review
  3. Article
  4. Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens.Microbiology and molecular biology reviews : MMBR · 2018
    Review
  5. Article
  6. Article
  7. Article
  8. Protective Immunity Elicited by Oral Immunization of Mice withFrontiers in cellular and infection microbiology · 2016
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stacy L AgarDepartment of Microbiology and Immunology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA.
Jian ShaDepartment of Microbiology and Immunology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA.
Wallace B BazeDepartment of Veterinary Sciences, University of Texas M. D. Anderson Cancer Center, Bastrop, TX 78602, USA.
Tatiana E ErovaDepartment of Microbiology and Immunology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA.
Sheri M FoltzDepartment of Microbiology and Immunology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA.
Giovanni SuarezDepartment of Microbiology and Immunology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA.
Shaofei WangDepartment of Microbiology and Immunology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA.
Ashok K ChopraCenter for Biodefense and Emerging Infectious Diseases, UTMB, Galveston, TX 77555, USA.

Funding

Task 7 (C29): Development of a Small Animal Model for Dengue N01AI30065 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · 2007 to 2009
$11.1M
Identification of New Antigens for a Plague VaccineR01AI064389 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CHOPRA, ASHOK K · 2005 to 2015
$3.8M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
NIAID NIH HHS N01 AI030065NIAID NIH HHS N01 AI064389NIAID NIH HHS N01 AI30065NIAID NIH HHS R01 AI064389NIAID NIH HHS T32 AI060549
6 · The paper itself

Abstract

Deletion of the murein (Braun) lipoprotein gene, lpp, attenuates the Yersinia pestis CO92 strain in mouse models of bubonic and pneumonic plague. In this report, we characterized the virulence of strains from which the plasminogen activating protease (pla)-encoding pPCP1 plasmid was cured from either the wild-type (WT) or the Deltalpp mutant strain of Y. pestis CO92 in the mouse model of pneumonic infection. We noted a significantly increased survival rate in mice infected with the Y. pestis pPCP(-)/Deltalpp mutant strain up to a dose of 5000 LD(50). Additionally, mice challenged with the pPCP(-)/Deltalpp strain had substantially less tissue injury and a strong decrease in the levels of most cytokines and chemokines in tissue homogenates and sera when compared with the WT-infected group. Importantly, the Y. pestis pPCP(-)/Deltalpp mutant strain was detectable in high numbers in the livers and spleens of some of the infected mice. In the lungs of pPCP(-)/Deltalpp mutant-challenged animals, however, bacterial numbers dropped at 48 h after infection when compared with tissue homogenates from 1 h post-infection. Similarly, we noted that this mutant was unable to survive within murine macrophages in an in vitro assay, whereas survivability of the pPCP(-) mutant within the macrophage environment was similar to that of the WT. Taken together, our data indicated that a significant and possibly synergistic attenuation in bacterial virulence occurred in a mouse model of pneumonic plague when both the lpp gene and the virulence plasmid pPCP1 encoding the pla gene were deleted from Y. pestis.

Indexed as

PlasmidsSequence DeletionAnimalsBacterial ProteinsCytokinesFemaleLethal Dose 50LipoproteinsLiverLungMicePlaguePlasminogen ActivatorsSpleenSurvival AnalysisVirulenceBacterial ProteinsCytokinesLipoproteinsPla protease, Yersinia pestisPlasminogen ActivatorsVirulence Factors

Identifiers

PMID19589835
PMCPMC2889417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.